Prior to high-throughput genomic sequencing, amplification of the oncogenic transcription factor MYCN was identified in 20% of neuroblastoma cases and associated significantly with high-risk disease and poor outcome [9,20,21,22,23,24,25]. This evidence concerns the gene MYCN and neuroblastoma.